428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)

Lewis, Karl ; Peris, Ketty ; Sekulic, Aleksandar ; Stratigos, Alexander ; Dunn, Lara ; Eroglu, Zeynep ; Chang, Anne Lynn ; Migden, Michael ; Li, Siyu ; Mohan, Kosalai ; Coates, Ebony ; Okoye, Emmanuel ; Baurain, Jean-François ; Bechter, Oliver ; Hauschild, Axel ; Butler, Marcus ; Hernandez-Aya, Leonel ; Licitra, Lisa ; Neves, Rogerio ; Ruiz, Emily ; Seebach, Frank ; Weinreich, David ; Yancopoulos, George ; Lowy, Israel ; Bowler, Timothy ; Fury, Matthew

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A260-A261 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível